

Neja Å amec

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3013475/publications.pdf>

Version: 2024-02-01

13
papers

225
citations

933447

10
h-index

1199594

12
g-index

13
all docs

13
docs citations

13
times ranked

274
citing authors

#	ARTICLE	IF	CITATIONS
1	OligoPrime: An Information System for Oligonucleotide Management. <i>Biomedical Engineering and Computational Biology</i> , 2021, 12, 117959722110419.	2.0	0
2	Cytoskeletal proteins as glioblastoma biomarkers and targets for therapy: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103283.	4.4	17
3	Large-Scale Transcriptomics-Driven Approach Revealed Overexpression of CRNDE as a Poor Survival Prognosis Biomarker in Glioblastoma. <i>Cancers</i> , 2021, 13, 3419.	3.7	14
4	Algorithmically Deduced FREM2 Molecular Pathway Is a Potent Grade and Survival Biomarker of Human Gliomas. <i>Cancers</i> , 2021, 13, 4117.	3.7	9
5	TRIM28 Selective Nanobody Reduces Glioblastoma Stem Cell Invasion. <i>Molecules</i> , 2021, 26, 5141.	3.8	16
6	Current Technologies for RNA-Directed Liquid Diagnostics. <i>Cancers</i> , 2021, 13, 5060.	3.7	14
7	Coding of Glioblastoma Progression and Therapy Resistance through Long Noncoding RNAs. <i>Cancers</i> , 2020, 12, 1842.	3.7	26
8	Analysis of miR-9-5p, miR-124-3p, miR-21-5p, miR-138-5p, and miR-1-3p in Glioblastoma Cell Lines and Extracellular Vesicles. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8491.	4.1	25
9	Anti-vimentin, anti-TUFM, anti-NAP1L1 and anti-DPYSL2 nanobodies display cytotoxic effect and reduce glioblastoma cell migration. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091530.	3.2	25
10	Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma. <i>Molecules</i> , 2020, 25, 490.	3.8	31
11	High FREM2 Gene and Protein Expression Are Associated with Favorable Prognosis of IDH-WT Glioblastomas. <i>Cancers</i> , 2019, 11, 1060.	3.7	16
12	Meta-Analysis and Experimental Validation Identified FREM2 and SPRY1 as New Glioblastoma Marker Candidates. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1369.	4.1	11
13	Glioblastoma-specific anti-TUFM nanobody for <i>in-vitro</i> immunoimaging and cancer stem cell targeting. <i>Oncotarget</i> , 2018, 9, 17282-17299.	1.8	21